

Developing oral drugs to halt neurodegeneration

BIO Biotechnology Entrepreneurship Bootcamp 13 June 2022 Session 14: Pre-seed/Seed Funding Pitch


No drugs alter progression of neurodegenerative diseases



20 years 100's clinical trials 0 drugs



Origami's concept: A precision medicine approach




• Disease selection: Clinical trials feasible & Patient population accessible

- Target selection: Fix the root cause of disease
- Drug selection: Choose best therapeutic modality



Despite \$2.8B spent on drugs for HD in 2021 alone, we still can't effectively treat Huntington's disease (HD)

- Caused by <u>mutation in Huntingtin protein (mHTT)</u>
- Characterized by loss of brain cells
- Affects all cells in the body
- Huntingtin protein is <u>critical</u> for normal function
- Lowering mHTT halts & reverses disease in animal models





HD is an orphan disease with \$9B projected revenue in 2030

- Affected: 185,000 WW
- <u>Orphan Disease</u> designation provides an expedited regulatory path
- Current symptomatic drugs: \$100K/annum/patient
- Estimated revenue for disease-modifying drug:
 185K patients x 25% market share x \$100K/patient/ yr = \$4B*
- Projected Industry Revenue in 2030: \$9.2B WW**

* Medical Market Economics evaluation for Origami, 8/2019



Leadership team: >30 assets advanced into clinic, 4 marketed drugs in Cystic Fibrosis



Beth Hoffman, Ph.D. Founder & CEO

25 years of CNS drug discovery experience, with over 30 assets advanced into the clinic and 4 marketed drugs for Cystic Fibrosis





Leslie Schulze Co-Founder & CFO

Over 20 years of finance experience in life sciences, including VC financing, non-dilutive funding, licensing and M&A





Christopher Smith, Ph.D. Advisor, Chemistry

20 years of industrial experience in neuroscience, oncology, immunological and metabolic disease therapeutic areas



Scientific advisors: World class key opinion leaders



Jody Corey-Bloom, M.D., Ph.D. Professor, UCSD Director, HD & AD Clinical Centers Translational research & clinical trials



Steven Finkbeiner, M.D., Ph.D.

Professor, Neurology & Physiology, UCSF Director, Taube/Koret Center of Neurodegenerative Disease Research & Center for Systems and Therapeutics, Gladstone Institutes



Kalpana Merchant, Ph.D.

President & CEO, TransThera Consulting Adjunct Professor, Feinberg School of Medicine, Northwestern University CEO & CSO roles at start-ups







Lucia Mokres, DVM

Regulatory, Clinical and Medical Affairs Founder & Principal, Araneae Biotech Consulting







Origami's solution: protein degraders selectively destroy mHTT protein

Selectively destroy mutant protein

Mutated Huntingtin protein (mHTT)



Spare normal protein



Normal Huntingtin protein (HTT)

- Goal: Remove toxic protein to enable restoration of normal function
- Targeted protein degradation (TPD): a powerful way to silence errant proteins
- Origami's approach is tailored to diseases of the brain



Origami has identified promising molecules


- Unique proprietary high throughput screen identified multiple small molecules
- Developed human HD neuronal models: Use enhances probability of success in clinical trials
- Our small molecules prevent HD pathology in human neurons



- Use of patient-derived cells enhances probability of success in the clinic
- Machine learning generates human disease models by integrating multiple layers of data
- Drives compound optimization and biomarker discovery




Normal No Treatment



Blue = cell body Red = neurites


- Use of patient-derived cells enhances probability of success in the clinic
- Machine learning generates human disease models by integrating multiple layers of data
- Drives compound optimization and biomarker discovery






Normal

Disease No Treatment






Blue = cell body Red = neurites

- Use of patient-derived cells enhances probability of success in the clinic
- Machine learning generates human disease models by integrating multiple layers of data
- Drives compound optimization and biomarker discovery





- Use of patient-derived cells enhances probability of success in the clinic
- Machine learning generates human disease models by integrating multiple layers of data
- Drives compound optimization and biomarker discovery



Multiple chemical assets have therapeutic attributes

ORI-113 and ORI-110 represent distinct chemical classes of mHTT protein degraders

ATTRIBUTE	ORI-113	ORI-110
Prevents mHTT protein aggregation	\checkmark	\checkmark
Reduces mHTT protein levels		
Selective for mHTT over wtHTT	\checkmark	\checkmark
Efficacious in human disease neurons	\checkmark	\checkmark
Brain penetrant		\checkmark
Efficacious in mouse HD model	In progress	In progress



Origami is pursuing a robust intellectual property strategy

- All assets discovered by Origami
- Patent filings include:
 - Composition of matter (5 scaffolds)
 - Method of use
 - o Expiry not before 2040
- Methods of selection (proprietary know-how) held as trade secrets



We have Preliminary Freedom to Operate (FTO)



Compared to competitors, Origami molecules selectively reduce mHTT and are systemically available

Origami Protein Degraders	Competitors	
Reduces mutant HTT Spares normal HTT	Reduces both normal and mutant HTT	
Systemic exposure	Brain only, may be limited to parts of brain	
Treats whole body, entire disease	Partially treats disease	
Oral delivery	Invasive delivery	
Democratization of access	Requires neurosurgeon & neurosurgical suite	

Reducing normal HTT may contribute to dose-limiting side effects



Huntingtin Protein Degrader Development Timeline

Hit-to-Lead	Lead Optimization	Pre-Clinical	Ph I/ II
— 9 mos —	18 mos	—— 12 mos——	— 27 mos—
Sood	Sorios A	Sa	rioc B

Seed	Series A	Series B	
Lead Selection In vivo POC	Advance Lead Asset and Backup Non-GLP Tox Clinical Candidate Selection	IND-Enabling API & CMC IND Approval	Phase I/ Phase II (Patients)
Build out science and management teams			

Hit-to-Lead Milestones:

Efficacy in human HD neurons
 Efficacy in rodent HD model
 Lead Selection



Origami's business thesis

Origami intends to generate clinical stage drug programs through internal research

- License most with large global pharmaceutical companies
- Develop a limited number of clinical programs independently
- Exit via large pharma acquisition or public capital

Recent Deals in Similar Spaces:

	Pharma Partnerships	Institutional Investment	Public Markets
Targeted Protein Degradation	Pfizer/Arvinas \$350M upfront, \$1B milestones	PAQ Therapeutics \$30M Series A	Monte Rosa Therapeutics IPO (preclin), \$850M valuation
Rare Diseases	Eli Lilly/ProQR RNA Therapeutic \$50M upfront, \$1.3B milestones	Kelonia Therapeutics Gene Therapy \$50M Series A	Parvaris Small molecules IPO (Phase 1), \$575M valuation
Neurodegenerative Diseases	UCB/Neuropore (pre-IND, PD) Small Molecule \$20M upfront, \$460M milestones	LEXEO Therapeutics Gene Therapy \$85M Series A	Vigil Neuroscience Small molecule IPO (Phase 1), \$395M valuation

\$2M Seed to show our drugs work in HD animal brains, select lead molecules using human disease models and make key hires

Goal: Select the best compounds to advance

Funding History: \$3.3M raised


- Founders: \$2.8M
- Y Combinator: \$0.5M

Seeking:

\$2M Seed Raise (9-12 month runway)

- \$0.2M raised to date
- \$12M post-money SAFE, 20% discount •

Seed Raise (\$2M) 9-12 month runway





Investment opportunity

- Origami has created an entirely new way to treat neurodegeneration

 Starting with Huntington's Disease
- Origami team has extensive experience in advancing drugs through clinical trials
- Multiple exit opportunities with excellent ROI
- If successful, this approach can be applied to other neurodegenerative disease such as Alzheimer's, Parkinson's, ALS, Frontotemporal Dementia.



Developing next-generation disease-modifying protein degraders



Origami has potential to impact millions of lives

Impact

Patients who would be plagued by neurodegeneration will not become symptomatic and will live healthy productive lives.

Scalability

Our drug discovery engine can scale to address the > 30 million patients with neurodegenerative diseases worldwide.



Origami Therapeutics: Oral drugs to halt neurodegeneration



Contact:

Beth J. Hoffman, Ph.D., President & CEO 805.558.2664 <u>beth@origamitherapeutics.com</u>

